Genera’s low false negatives

By Dylan Bushell-Embling
Wednesday, 15 October, 2008


Pilot clinical trials of Genera Biosystems' [ASX: GBI] new PapType HPV detection test have shown that the test gives improved detection rates of cervical cancer than the market leader test.

Currently Qiagen's Hybrid Capture 2 test (HC2) is the only FDA-approved test for cervical cancer screening.

But in Genera's latest trials, PapType outperformed the HC2 test, returning a false negative rate of seven per cent, compared to a 27 per cent false negative rate with HC2.

Genera believes the results are very encouraging, although they are not yet conclusive.

For example, all the women in the study already had an abnormal pap smear. According to Genera, trials from the general population will need to be conducted before the superiority of PapType can be confirmed.

Related Articles

New species of bacteria discovered in prostate cancer patients

Researchers have discovered the genetic blueprints of 18 new bacterial species in prostate cancer...

Award-winning system automates vial filling for cell therapy

Celleo's Larkem V40 — created to address one of the bottlenecks holding back cell...

Air pollutant exposure linked to glaucoma, cataracts and suicide

People who are exposed to high levels of air pollution are more likely to develop glaucoma and...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd